Clinical significance and usefulness of soluble heparin binding-epidermal growth factor in gastric cancer

摘要: AIM: To evaluate the clinical usefulness of soluble heparin-binding epidermal growth factor (sHB-EGF) as a serum biomarker for gastric cancer (GC). METHODS: Serum sHB-EGF levels were measured by commercially available human HB-EGF ELISA Kit and compared among 60 normal controls, 30 high-risk patients, 37 early (EGC), advanced (AGC) through ANOVA test. Correlations between clinicopathological features GC analyzed Spearman’s correlation. The diagnostic performance was evaluated receiver operating characteristic (ROC) curve logistic regression analysis. RESULTS: significantly higher in AGC group (314.4 ± 127.5 pg/mL) than EGC (165.3 123.2 pg/mL), (98.7 67.3 control (94.7 83.6 groups (post-hoc Bonferroni, all P < 0.001), respectively. also (P = 0.049) 0.006) groups. Clinicopathologically, closely correlated with depth invasion (T-stage, γs 0.669, lymph node metastasis (N-stage, 0.407, distant (M-stage, 0.261, 0.030). ROC analysis demonstrated remarkable potential sHB-EGF. CONCLUSION: is stage can be promising serological GC.